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Abstract
The above titled paper examined the Food and Drug Administration’s (FDA’s) warning letters and notice 
of violations (NOV) over a 10-year period.  Findings from this content analysis reinforced what has been the 
primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the fair balance of risk 
and benefit information.  As opposed to another analysis in 2026 about this still being an issue, is there anything 
that can be done to prevent this problem from continuing?
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In the research paper and content analysis addressed by this commentary, Hyosun Kim thoroughly examines a 10-year stretch of Food and Drug Administration (FDA) warning 
letters and notice of violations (NOV) to identify problem 
areas in online direct-to-consumer advertising (DTCA).1 The 
author sought to answer four research questions:
•	 What online promotions were most targeted by the FDA?
•	 Which drug categories were most targeted?
•	 What are the FDA’s most common complaints/areas of 
issue?
•	 Which allegations match which online promotion? 
Each research question was answered by the author, as 
“marketer controlled” elements such as the medication website 
were the most cited, cancer the most prominent medication 
category and risk information problems the most common 
complaint. Outside of the article’s organization and placement 
of certain material, I had minimal qualms with the research and 
think it brings back into play the most debated subject in the 
DTCA realm. The author’s results pointed to the FDA’s focus 
and an area pharmaceutical manufacturers still to this day, over 
18 years after the moratorium on DTCA was lifted, struggle 
– the ‘fair balance’ requirement in the amount of risk versus 
benefit information presented in any promotional item and 
outlet (which means even on the 140-character limit microblog 
site Twitter). The remainder of this commentary will address 
Kim’s article, examine other current DTCA research, and pose 
possible solutions in the form of questions that need to be 
addressed with future research.
As Kim’s article highlights, the FDA’s decision in 1997 to 
lifts its moratorium on DTCA led to a rapid increase in 
promotional spending, peaking in the mid-2000s. This 
created an overwhelming environment for the FDA to follow, 
track, and monitor, with 262 letters identified over the 10-
year period (all letters – not just the ones focused online). 
Also during that time, the FDA has extensively researched 
consumer response to DTCA and put out guidance documents 
for the pharmaceutical industry to better understand how to 
exist in the space without consequence.2-5 Still, though, the 
fair balance requirement and how risks and benefits should 
be communicated is a complicated issue. From an overall 
perspective, the practice of DTCA has been postulated to have 
benefits and risks in and of itself. Through both research and 
opinion papers, pros and cons for the impact of DTCA in the 
areas of drug utilization, the physician-patient relationship, 
consumer knowledge/education, health outcomes, adherence, 
broad social outcomes, and legal issues have been examined.6 
Further, given the practice only exists in the United States 
and New Zealand, it begs the question as to whether or not it 
should even exist at all? Could DTCA be altered in some way 
or removed altogether and put an end to the seemingly never-
ending ‘fair balance’ issue? 
Over the last few years, numerous media and academic outlets 
from Prevention Magazine,7 to the Huffington Post,8 and even 
Nature Biotechnology9 have addressed the big picture question 
surrounding DTCA from both the positive and negative side. 
Further, various associations have also put their two cents 
in, including the American Academy of Physician Assistants 
(AAPA), which states “that any DTCA by pharmaceutical 
companies be based on disease state only, without mention 
of a specific drug by name or category,”10 and even more 
recently (November 2015), the American Medical Association 
(AMA) called for an all-out ban on DTCA. The AMA felt a 
ban “reflects concerns among physicians about the negative 
impact of commercially-driven promotions, and the role that 
marketing costs play in fueling escalating drug prices …DTCA 
also inflates demand for new and more expensive drugs, even 
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when these drugs may not be appropriate.”11 Thus, what does 
this mean for the future of DTCA and how can the fair balance 
dilemma be solved? 
Over the past 6 years, my colleagues and I have researched 
the impact of disease-specific DTCA. Disease-specific DTCA, 
also referred to as help-seeking, is defined by the FDA as “one 
which discusses a disease or condition and makes no mention 
or representation of a particular drug or device.”12 Under this 
guidance, these communications are exempt from regulation 
by the agency unless there is only one drug or device used in 
the disease/condition. Thus, these ads focus only on the disease 
state and theoretically eliminate the need for a ‘fair balance’ of 
risk and benefit information as no specific product is mentioned 
and the only distinguishing factor in a disease-specific DTCA 
being the company name and logo. Beginning in 2010 and 
up to the present day, we have compared disease-specific 
DTCA to product-specific DTCA in drug inquiry intention 
and information seeking behavior,13 effectiveness from an 
attitudinal perspective,14 and animation15; examined celebrity, 
endorser type, and gender roles in disease-specific DTCA16,17; 
and, recently, disease-specific DTCA’s role in medication 
adherence.18 From a consumer response perspective, what has 
all the research told us? That while certain aspects of product-
specific DTCA are more noticed or memorable to consumers, 
the overall intent of the ads (inducing information seeking and 
conversations with physicians) is achieved more significantly 
with disease-specific DTCA. 
Kim accomplished at least one thing with this detailed content 
analysis; it has indirectly renewed a debate that has existed 
since Boots Pharmaceutical showed us the first DTCA for 
Rufen®.19 Thus, what is the best solution? Is it a ban of DTCA 
altogether? Is it a switch to disease-specific DTCA only as 
the AAPA would have and our research shows would not 
necessarily be detrimental to the manufacturers? What about 
a dollar-for-dollar requirement of manufacturers in the two 
areas (ie, for every dollar spent on product-specific DTCA 
the company must also spend that amount on disease-specific 
DTCA)? Ultimately more research, both from academicians 
and the FDA, should continue to examine this topic. My own 
next steps include assessing the risk-benefit relationship in 
disease versus product-specific ads and further analyzing the 
possible impact of DTCA on medication adherence. I end 
with a challenge to all of those who analyze and study DTCA. 
Let’s work together to eliminate the fair balance dilemma, 
either through alternative measures/regulations or improving 
the current structure and practices to eliminate the gray, 
make decisions for manufacturers clear, and give the general 
consumer fair and balanced information.
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